Mizuho Financial Group Reports New 6% Stake in Drugs Made In America Acquisition Corp.

Mizuho Financial Group, Inc., a Japanese parent holding company, filed a Schedule 13G on May 14, 2026, reporting a new 6.0% ownership stake in Drugs Made In America Acquisition Corp. (DMAA). As of the event date on March 31, 2026, Mizuho reported beneficial ownership of 2,000,000 common shares. The filing indicates that these shares are held directly by Mizuho Securities USA LLC, a wholly-owned subsidiary. Consequently, Mizuho Financial Group, Inc., along with its subsidiaries Mizuho Bank, Ltd. and Mizuho Americas LLC, may be deemed indirect beneficial owners of the securities. The filing includes certifications that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This initial filing marks a significant position for the financial group in the acquisition corporation, as the previous ownership percentage was reported at 0.0%. The filing was signed by Takahiro Katsura, Managing Director, under power of attorney for the reporting entities.